Search

Displaying results 4081 - 4090 of 10000 in total
  1. Drug

    Terbutryn

    go.drugbank.com/drugs/DB08215
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Propatyl nitrate

    go.drugbank.com/drugs/DB13255
    Investigational

    Categories: Vasodilators Used in Cardiac Diseases
  3. Drug

    Enalkiren

    go.drugbank.com/drugs/DB03395
    Experimental

    Categories: Agents Acting on the Renin-Angiotensin System
  4. Drug

    Aminacrine

    go.drugbank.com/drugs/DB11561
    Investigational

    It is also used as an intracellular pH indicator.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  6. Drug

    Tinidazole

    go.drugbank.com/drugs/DB00911
    ApprovedInvestigational

    A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.

  7. Drug

    Bimoclomol

    go.drugbank.com/drugs/DB06258
    Experimental

    Bimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.

  8. Drug

    Camazepam

    go.drugbank.com/drugs/DB01489
    ExperimentalIllicit

    In the United States camazepam is regulated as a Schedule IV controlled substance. … Similarly to other drugs in its class, it has antxiolytic, anticonvulsant, hypnotic, and skeletal muscle relaxant properties.

  9. Drug

    XL281

    go.drugbank.com/drugs/DB05190
    Investigational

    Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. … XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers.

  10. Drug

    MIP-1095 I-131

    go.drugbank.com/drugs/DB14978
    Investigational

    MIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).